表皮生長因子受體—酪氨酸激酶抑制劑(epidermal growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI) 為現今治療後期非小細胞肺癌(non-small-cell lung cancer) 的重要標靶藥物。然而，約有1% 的EGFR-TKI 使用者會發生藥物引起之間質性肺部疾病(interstitial lung disease)。EGFR-TKI 所引發之間質性肺部疾病可導致嚴重之後遺症，甚至可能致命，而且早期診斷與早期停止EGFR-TKI 可以明顯改善患者的預後，因此臨床醫療工作者應對於此一臨床狀況的診斷與處置了然于胸。有鑒於此，本文針對發表於2018 年9 月30 以前之相關於此類間質性肺部疾病的文獻進行系統性之探討與報告，以期精進我輩對於後期肺癌病人之照護能力。

The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the most important target therapy used to treat non-small-cell lung cancer to date. However, it has been reported that approximately 1% of the EGFR-TKI users developed interstitial lung disease, and some of them ended up with severe morbidity and even mortality. With an early diagnosis and treatment of this type of interstitial lung disease, the outcomes of the patients affected significantly improve. As such, it is important for all clinicians to always keep in mind this possible, serious complication of using EGFR-TKIs and how the condition is best managed. In this article, we aim at improving healthcare practitioners’ abilities to manage this EGFR-TKI associated interstitial lung disease by producing a systemic review on the literature published before 30th of September, 2018.